We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.
In Vivo is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183
Express Scripts pays $4.7bn for WellPoint's NextRx business
15 Apr 2009
Executive Summary
Express Scripts announced it will acquire health plan administrator WellPoint's three NextRx pharmacy benefit management subsidiaries--NextRx Inc., NextRx Services Inc., and NextRx LLC--for $4.7bn, or approximately $3.3bn cash plus $1.4bn in Express common stock (based on the market average, this could mean about 29.4mm shares). Express is financing the transaction using money from a debt sale.
Deal Industry
Pharmaceuticals
Services
Deal Status
Final
Deal Type
Acquisition
Full Acquisition
Includes Contract
Payment Includes Cash
Payment Includes Stock
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?